LMW-DXS abrogates procoagulant and complement triggering action of DVs. (A) Clotting times were determined after recalcification of 50% citrated plasma in the absence (control) or presence of DVs and LMW-DXS at the depicted concentrations. DVs provoked a significant reduction in clotting time (*P < .05 vs control), which was significantly reversed by 10 μg/mL of LMW-DXS (^oP < .05). LMW-DXS (100 μg/mL) completely prevented clot formation despite the presence of DVs. Data are expressed as means ± SD of 3 independent experiments. (B) LMW-DXS abrogates prothrombinase assembly on DVs. Prothrombinase assays were performed in the presence of 5 × 10⁷ DVs/mL and in the absence or presence of LMW-DXS at the given concentrations, and thrombin generation was determined after 2 and 5 minutes (n = 3 ± SD). DXS (100 μg/mL) abolished prothrombinase assembly (*P < .05 vs control). (C) Inhibition of DV-dependent C3 turnover by 100-1000 μg/mL of LMW-DXS. In the control (top left panel), 20% NHS was incubated for 30 minutes at 37°C. DVs/mL (10⁸) were added to 20% NHS in the absence or presence of LMW-DXS at the depicted concentrations. Inhibition of C3 turnover (arrows) was observed at 100 μg/mL of LMW-DXS. Results shown are representative of 3 independent experiments.